Skip to main content
padlock icon - secure page this page is secure

CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone–proguanil against falciparum malaria in Vietnam

Buy Article:

$52.00 + tax (Refund Policy)

Summary Objectives 

To study a new combination, based on dihydroartemisinin and piperaquine (CV8) and atovaquone/proguanil (Malarone) for treatment of uncomplicated falciparum malaria in Vietnam. Methods 

Vietnamese adults with falciparum malaria were allocated randomly to treatment with dihydroartemisinin/piperaquine/trimethoprim/primaquine 256/2560/720/40 mg (CV8, n = 84) or Malarone 3000/1200 mg (n = 81), both over 3 days. Patients were followed-up for 28 days. Results 

All patients recovered rapidly. The mean (95% CI) parasite elimination half-life of CV8 was 6.8 h (6.2–7.4) and of Malarone 6.5 h (6.1–6.9) (P = 0.4). Complete parasite clearance time was 35 (31–39) and 34 h (31–38) (P = 0.9). The 28-day cure rate was 94% and 95%, respectively (odds ratio 0.84, 95% CI 0.18–3.81). No significant side-effects were found. Conclusion 

CV8 and Malarone are effective combinations against multi-drug resistant falciparum malaria. CV8 has the advantage of a low price.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Plasmodium falciparum; Vietnam; atovaquone; combination therapy; dihydroartemisinin; piperaquine; primaquine; proguanil; trimethoprim

Document Type: Research Article

Affiliations: 1:  Division of Infectious Diseases, Tropical Medicine & AIDS, Academic Medical Center, Amsterdam, The Netherlands 2:  Tropical Diseases Clinical Research Center, Cho Ray Hospital, Ho Chi Minh City, Vietnam 3:  Binh Thuan Provincial Malaria Station, Phan Thiet, Binh Thuan Province, Vietnam

Publication date: February 1, 2004

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more